Cancer Genetics — Vyant Bio — Q1 2022 Earnings Presentation
14 slides from Cancer Genetics's earnings presentation, May 16, 2022
Slide 1: Conference Call & Webcast for the First Quarter 2022
a a " 7 WYANT ic HUMAN-POWERED DRUG DISCOVERY Nasdaq: VYNT Conference Call & Webcast for the First Quarter 2022 Monday, May 16, 2022 - 4:30pm ET "a
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that exist in our operations and business environment, which may be beyond our co
Slide 3: Drug Discovery Needs a Paradigm Shift
DRUG DISCOVERY Needs a Paradigm Shift Underperformance of W for Predicting Dru: Late Introduc R&D Process | VYANT:ic Defines a New Approach Deep Expertise and Global Presence in Drug Discovery Human Biology and Data Science Driven Proprietary Discovery Engine Focused on Efficiently Discovering Novel
Slide 4: Therapeutic Pipeline
Therapeutic Pipeline Our Therapeutic Assets PRECLINICAL CLINICAL Parkinson's Disease my * Weare in partnerships for the use of artificial intelligence systems with Atomwise for the discovery of a novel Rett Syndrome compound and Cyclica for the discovery of a novel CDKLS compound VYANTic v Nasdaq: V
Slide 5: First Quarter 2022 Highlights
a FIRST QUARTER 2022 HIGHLIGHTS VYANTic Nasdaq: VYNT
Slide 6: Leveraging Human Biology and Data Science to Discover New Therapies
iPSC* organoids for screen ! accelerate drug discovery by redu drive clinical translation of di WYANT ic Leveraging Human Biology and Data Science to Discover New Therapies for Neurodevelopmental and Neurodegenerative Disorders _ ol
Slide 7: Human microOrgan Discovery Platform
Human microOrgan™ Discovery Platform Paradigm for high-throughput clinic-based screening Drive Successful Clinical Outcomes Through Patient-Based Discovery 3 70 my RQ ‘) )\ we Discovery = Targets & Hits Novel & Repurposed ¥ Patient-derived iPSC Organoids Biomarker-based Screening Value Creation Esta
Slide 8: Rett neurospheroids display a unique functional phenotype
Rett neurospheroids display a unique functional phenotype « Rett neurospheroids display a distinct functional signature ¢ Proprietary AnalytixX algorithms extract and quantify several features of the calcium signal FLIPR AssayAnalytix AssayAnalytix E Feature extraction Phenotypic distinction Control
Slide 9: Rett neurospheroids show consistent and robust phenotypic signatures
Rett neurospheroids show consistent and robust phenotypic signatures Rett disease functional phenotype is robust across == Rett neurospheroid multiple distinct differentiation batches and screens — Control neurospheroid Key features to distinguish RTT and control phenotypes Feature Class Feature [Si
Slide 10: VYNT-0126 showed a dose-dependent rescue of the Rett functional phenotype
| VYNT-0126 showed a dose-dependent rescue of the Rett functional phenotype Global recovery with VYNT-0126 Features change by concentration Rescue of key parameters 100 o 3s =s, ‘100 ° 3 a a = 3 2 vs ge 8 = 75 2 e 3 = a 3 so o § - i o¢ 3 3 i 25 ma Z 3 @ 25 75 Hy ES 0 1 | 100 & ® 09), = 9 ECFEHE MV?
Slide 11: VYNT-0126 has a distinct mechanism compared to advanced clinical candidates
| VYNT-0126 has a distinct mechanism compared to advanced clinical candidates VYNT-0126 Clinical candidate 1 Clinical candidate 2 100: 100 75: 75 100 100. o—+ Fs yt 100 = 5 = 75 3 # 75 75 5 > | Ps > > z S 50. | bso 8 8 50 8 5 50. 50 8 8 / g 8 g g g & 2 A ro é a= 8 2 3 = ia ba = SS 4 an anaranaranan
Slide 12: Financial Discussion
FINANCIAL DISCUSSION UNITED STATES. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20500 FORM 10-Q SS QUARTYRLY REPORT FLAS ANT TO SECTION 11OR 1) OF Forte Quercy Peed ade Merch, 202 YYANT BIO, INC, 2390S Hote Mute 6 (Akon fpimgat cian io) Cle) Nephi mane eg ac eT Tae oT aa The Rebate TE rome o
Slide 13: Drug Discovery Needs a Paradigm Shift
DRUG DISCOVERY Needs a Paradigm Shift Underperformance of W for Predicting Dru: Late Introduc R&D Process | VYANT:ic Defines a New Approach Deep Expertise and Global Presence in Drug Discovery Human Biology and Data Science Driven Proprietary Discovery Engine Focused on Efficiently Discovering Novel
Slide 14: Investor Contact
Nasdaq-VYNT “@ nBi aay, ey NeGrolagica at Diseas Investor Contact: Jennifer K. Zimmons. Ph.D. Investor Relations Zimmons International Communications, Inc. Email: jzimmons@zimmonsic.com Phone: +1.917.214.3514 ve sa